Best Buy Stocks -

: Up over 267% YTD after reporting positive clinical data for its RAS/MAPK pathway-driven cancer treatments.

: Up over 115% YTD (as of April 27) following a recent 21% surge and bullish outlook on its manufacturing turnaround. Analyst "Best Buy" Recommendations for 2026 best buy stocks

Expert services like Morningstar and The Motley Fool have identified these as top picks for long-term holding. NASDAQ:NVDA : Up over 267% YTD after reporting positive